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Abstract
The recent swine H1N1 influenza outbreak demonstrated that egg-based vaccine manufacturing has an Achille’s heel: its
inability to provide a large number of doses quickly. Using a novel manufacturing platform based on transient expression of
influenza surface glycoproteins in Nicotiana benthamiana, we have recently demonstrated that a candidate Virus-Like Particle
(VLP) vaccine can be generated within 3 weeks of release of sequence information. Herein we report that alum-adjuvanted
plant-made VLPs containing the hemagglutinin (HA) protein of H5N1 influenza (A/Indonesia/5/05) can induce cross-reactive
antibodies in ferrets. Even low doses of this vaccine prevented pathology and reduced viral loads following heterotypic lethal
challenge. We further report on safety and immunogenicity from a Phase I clinical study of the plant-made H5 VLP vaccine in
healthy adults 18–60 years of age who received 2 doses 21 days apart of 5, 10 or 20 mg of alum-adjuvanted H5 VLP vaccine or
placebo (alum).Thevaccine waswelltoleratedatall doses. Adverse events(AE)weremild-to-moderate andself-limited.Painat
the injection site was the most frequent AE, reported in 70% of vaccinated subjects versus 50% of the placebo recipients. No
allergic reactions were reported and the plant-made vaccine did not significantly increase the level of naturally occurring
serum antibodies to plant-specific sugar moieties. The immunogenicity of the H5 VLP vaccine was evaluated by
Hemagglutination-Inhibition (HI), Single Radial Hemolysis (SRH) and MicroNeutralisation (MN). Results from these three assays
were highly correlated and showed similar trends across doses. There was a clear dose-response in all measures of
immunogenicity and almost 96% of those in the higher dose groups (2610 or 20 mg) mounted detectable MN responses.
Evidence of striking cross-protection in ferrets combined with a good safety profile and promising immunogenicity in humans
suggest that plant-based VLP vaccines should be further evaluated for use in pre-pandemic or pandemic situations.
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Introduction
The recent swine H1N1 influenza pandemic (pH1N1) revealed
the limitations of the current influenza vaccine manufacturing
technologies. On May 26, 2009, the WHO recommended rapid
development of vaccines and the first reassortant virus was
available on May 27 2009 [1]. Although Wyman and colleagues
had predicted in 2007, that egg-based manufacturing would be
able to supply at least 60 million vaccine doses within 5 months of
the declaration of a pandemic [2], the actual vaccine output in the
2009-10 pH1N1 pandemic was much lower. In fact, only 3 million
doses of live attenuated vaccine were available at 5 months. The
first doses for split vaccine became available shortly thereafter but
at levels far below expectations. Fortunately, the pH1N1 strain
had a low mortality rate compared to the 1918-19 pandemic
strain. Had the pH1N1 pandemic had a higher severity index, the
global human cost of the delays in egg-based vaccine production
could have been catastrophic.
It is ironic that the world’s attention had been focused on H5N1
viruses for more than a decade when pH1N1 emerged. It is
important that the global sense of relief at the relatively benign
nature of the pH1N1 pandemic should not lull us into
complacency regarding H5N1 influenza and other potential
pandemic strains. Although human-to-human spread has eluded
H5N1 viruses to date, a total of 498 human cases have been
reported to the WHO with a crude fatality rate of 59% (as of May
6, 2010). Continued hyper-mutation of H5N1 strains is occurring
worldwide in avian populations and reassortment with an
influenza strain actively circulating in humans is always a serious
threat. Jackson S and colleagues have recently shown that such
reassortment can readily occur between human H3N2 and avian
H5N1 strains in ferrets [3]. In parallel, Li and colleagues have
shown that reassortment between a low pathogenicity avian H5N1
strain and a human H3N2 strain can yield a new strain highly
pathogenic for mice [4]. This latter reassortant H5N1 strain had
acquired only the PB2 segment from the human strain. Regardless
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of the ‘next’ pandemic strain, our recent experience with pH1N1
demonstrate clearly that the current, egg-based manufacturing
system would not be able to respond quickly enough in the face of
a highly pathogenic influenza virus adapted for rapid human-to-
human spread.
We have recently described a plant-based manufacturing
technology that can produce vaccine doses within one month of
the sequencing of a pandemic strain [5]. This is accomplished by
the cloning the novel hemagglutinin gene into a well-characterized
vector followed by transient expression in Nicotiana benthamiana
plants. Five to six days after infection, plants are harvested and the
Virus-Like Particle (VLP) vaccine is purified. This paper describes
the efficacy of two doses of plant-made VLPs bearing the H5 from
A/Indonesia/5/05 against cross-clade lethal challenge in ferrets.
We also describe the first use of any plant-made VLP vaccine in
humans: in this case, safety and early immunogenicity following
two intramuscular (IM) doses of an H5-VLP candidate vaccine. In
addition to routine safety monitoring, we also determined whether
or not IgG and IgE antibodies specific for plant glycans were
induced by this novel vaccine candidate.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Vaccine production
The H5 VLP vaccine was produced as described in D’Aoust et al
[6]. Briefly, whole N. benthamiana plants (41–44 days old) were
vacuum infiltrated in batches with an Agrobacterium inoculum
containing the H5 expression cassette. Six days after infiltration,
the aerial parts of the plants were harvested and homogenized in
one volume of buffer [50 mM Tris, 150 mM NaCl: 0.04% (w/v)
Na2S2O5, pH 8.0]/kg biomass. The homogenate was pressed
through a 400 mm nylon filter and the fluid was retained. The
solution was brought to pH 5.360.1 with 5 M acetic acid and
heated to 4162uC for 15 minutes to allow aggregation of
insolubles which were then pelleted at room temperature in a
continuous-flow SC6 centrifuge at 1.2 L/min. The supernatant
was mixed with diatomaceous earth (1% w/v), adjusted to
pH 6.060.1 with TRIS base and passed through a 0.45/0.2
micron filter. The extract was then concentrated by tangential flow
filtration (TFF) on a 500,000 Da MWCO membrane and
diafiltered against 50 mM NaPO4, 500 mM NaCl and 0.005%
(v/v) Tween 80 (pH 6.0). Formaldehyde was added to reach
0.0125% final concentration and the remaining insolubles
removed by microfiltration.
This clarified extract was then passed through a Poros HQ
column equilibrated at pH 7.5 with 50 mM Tris-HCl -0.01%
Tween 80. The flow-through was captured on a Poros HS column
equilibrated in 50 mM NaPO4, 0.01% Tween 80 (pH 6.0)(Ap-
plied Biosystems, USA). After washing with 50 mM NaPO4,
65 mM NaCl, 0.01% Tween 80 (pH 6.0), the VLPs were eluted
with 50 mM NaPO4, 500 mM NaCl, 0.01% Tween 80 (pH 6.0)
and then captured on a Poros EP 250 coupled to bovine fetuin
(30 mg fetuin/mL Poros EP 250 matrix)(Desert Biologicals,
Australia) as recommended by the manufacturer and equilibrated
in 50 mM NaPO4, 150 mM NaCl (pH 6.0). The column was
washed with 50 mM NaPO4, 400 mM NaCl, (pH 6.0) and the
VLPs were eluted first with 1,5 M NaCl, and then water
containing 0.0005% Tween 80. The purified VLPs were
concentrated by TFF on a 300,000 Da MWCO membrane,
diafiltered against formulation buffer (100 mM PO4, 150 mM
NaCl, 0.01% Tween 80 at pH 7.4) and passed through a 0.22 mm
filter for sterilisation.
Vaccine characterization
Electron microscopy was performed as previously described by
D’Aoust et al [6]. A quantitative SRID assay was performed
essentially as described by Wood et al [7] with the following
modifications. Reference antibodies and HA antigen reagents for
the influenza A/Indonesia/5/2005 strain were supplied by the US
FDA CBER (Kensington, MD). The pre-treatment buffer for both
the H5 VLP and reference antigens included 1% Triton X-100.
The SRID assay was used to estimate HA content of the H5 VLP
vaccine.
SDS–PAGE analysis of VLP preparations was performed on
pre-cast gels, Criterion
TM XT 4–12% Bis-Tris (Bio-Rad Labora-
tories Hercules, CA). Samples were mixed with 4X SDS sample
buffer with DTT (EMD Chemicals Inc., Gibbstown) and 2.5 mgo f
protein was loaded per lane. Gels were processed according to the
manufacturer’s instructions and stained with BioSafe
TM Coomas-
sie G-250 (Bio-Rad Laboratories Hercules, CA).
Endotoxin levels were determined by the Limulus amebocyte
lysate test kit (QCL-1000, Lonza, Wakersville, MD) using the
internal Escherichia coli 0111:B4 control.
Detection of residual DNA was performed with the PicoGreenH
fluorescent dye assay (Invitrogen Canada, Burlington, ON) and
measured by fluorometry using Lambda DNA for the standard
curve (Invitrogen Canada, Burlington, ON).
Ferret Vaccination and Challenge
The ferret study was approved by the Institutional Animal Care
and Use Committee (IACUC) of the Southern Research Institute
(SRI Birmingham, AL). Male Fitch ferrets were castrated,
descented and demonstrated to be seronegative negative for
representative circulating human influenza A strains prior to
shipment to Southern research Institue(, 6–8 months old, 0.8–
1.6 kg, Triple F Farms, Sayre, PA). The ferrets were vaccinated
twice intramuscularly on days 0 and 21 with H5 VLP vaccine (0.7,
1.8, 3.7 or 11.0 mg HA formulated with alum (AlhydrogelH:
0.5 mg aluminium per 0.5 mL dose) or with placebo (PBS +
alum). Eight animals per group in the 1.8 or 3.7 mg vaccine and
placebo groups were challenged intranasally 45 days after the 21
day boost with a lethal dose of A/Vietnam/1203/04 H5N1 clade
1 virus (10 X Ferret Lethal Dose50). Animals were monitored for
weight loss, temperature and loss of activity weekly during
vaccination and daily during challenge. All surviving animals
were euthanized 14 days post-challenge. Three challenged animals
in each group were sacrificed 3 days after challenge and their lungs
and nasal turbinate tissues were collected, weighted, snap frozen in
liquid nitrogen until used for virus titres. Homogenized samples
were serially diluted 10-fold and inoculated into viable 10 to 11
day old embryonated hen’s eggs and viral titers were measured by
the Egg Infectious Dose50 (EID50) assay. Data are expressed as
log10EID50/mL using the Reed-Muench method [8]. Blood was
collected from anesthetized ferrets via the anterior vena cava
before the first and second immunization as well as 14 days after
the second immunization. Sera were stored in aliquots at 220uC
until use.
Assessment of immune response
Hemagglutination Inhibition assay. The Hemagglutina-
tion inhibition (HI) assay was performed according to WHO
recommendation [9] using whole inactivated virus for H5N1
strains: A/Indonesia/5/05 (homologous subclade 2.1 strain:
Development of Plant-Made Virus-Like Particle
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01/2005 (subclade 2.2: NIBSC, Potters Bar, UK) and A/turkey/
Turkey/1/05 (subclade 2.3: NIBSC). Briefly, sera were pre-treated
with receptor-destroying enzyme II (RDE II) (Denka Seiken Co.,
Tokyo, Japan) overnight at 37uC and then PBS (Thermo
Scientific, Rockford, IL) was added to create two dilutions (1:8
and 1:10). Sera were serially diluted 2-fold in V-bottom microtiter
plates. Twenty five mL of test virus (2–8 HAU/50 mL) were added
to each well and plates were incubated at room temperature for
30 min (ferret sera) or 90 min (human sera) prior addition of 0.5%
horse erythrocytes (Lampire Biologicals, Pipersville, PA). Plates
were incubated at room temperature for 60 to 90 min and HI
titers were defined as the reciprocal of the highest dilution causing
complete inhibition of hemagglutination. Seroconversion was
defined as a fourfold increase in HI titer or from baseline (#8)
to HI titers e32. Seroprotection was defined as the proportion of
subjects with HI titer $40. For the Phase 1 clinical trial, HI titers
was evaluated according to the EU EMEA CHMP criteria [10] for
non-elderly adults (seroprotection .70%; seroconversion or
significant increase.40%; geometric mean titers ratio GMR
increases .2.5).
Microneutralisation Assay. Microneutralization (MN) assays
were performed as previously described [11] 21 days after the
booster injection, using living H5N1 virus A/Indonesia/5/05
(homologous strain of subclade 2.1, provided by the CDC,
Atlanta, GA) and the living H5N1 virus A/Vietnam/1203/2004
(heterologous strain of clade 1, provided by the CDC).
Single Radial Hemolosyis Assay. Single radial hemolysis
(SRH) was performed at the University of Siena, Italy, against
whole inactivated A/Indonesia/5/2005 (H5N1) virus (subclade
2.1 strain: CBER). The SRH was modified slightly from the
method described by Schild et al [12]. Briefly, 2 sets of SRH plates
were prepared using 10% turkey erythrocytes (v/v of assay buffer)
with 2000 Hemagglutinin units (HU)/mL of whole inactivated
virus. Serum samples were heat inactivated at 56uC for 30 min,
and serial 2-fold dilutions were prepared with assay buffer. Serum
dilutions were added to the plates (6 mL final volumes) on
duplicate plates and both pre and post-vaccination sera were
titrated simultaneously. Laboratory staff was blind to group
assignment. The diameters of the haemolytic areas were
measured using a Transidyne Calibrating Viewer (Transidyne
General Corporation, Ann Arbor, MI). Haemolysis Area ,4m m
2
was considered negative, between 4 and 25 mm
2 was considered
positive but not protective and .25 mm
2 was considered
protective, as per EU EMEA CHMP guidelines [10]. Each test
run included negative and positive controls: the latter was
hyperimmune sheep serum provided by CBER.
Antibody Response to Plant Glycans
Ninety-six-well plates were coated overnight at 4uC with 50 mL
of either avidin (1 mg/mL) derived from egg white: (Sigma-
Aldrich, St-Louis, MO) or recombinant avidin expressed in corn
as a source of plant glycans (1 mg/L: Sigma-Aldrich) in 50 mM
sodium carbonate buffer (pH 9.6). The presence of plant-specific
xylose and fucose on the recombinant corn avidin was established
by Western blot. Plates were washed with PBS containing 0.1%
Tween-20 (PBS-T) and blocked with 1% casein in PBS-T
(blocking solution) for 1 h at 37uC. The plates were then incubated
with serial two-fold dilutions of sera in blocking solution for 1 h at
37uC. The plates were washed (PBS-T) and incubated for 1 h at
37uC with HRP-conjugated donkey anti-human IgG (H+L)
(Jackson ImmunoResearch Inc.) or HRP-conjugated goat anti-
human IgE (Sigma-Aldrich). Both conjugates were diluted at
1:10,000 in blocking solution. HRP activity was detected by
addition of 100 ml SureBlue TMB Microwell Peroxidase Substrate
(KPL, Kirkegaard & Perry Laboratories, Inc.). After 20 minutes at
room temperature, the enzymatic reaction was stopped with
100 ml 1N HCl and OD was determined at 450 nm. Differences
pre- and post-immunization were calculated as the highest titer
giving a difference .0.1 OD. Rabbit antibodies raised against
xylose or fucose residues (AgriSera) were used as controls.
‘Positive’ reactions were defined as a two-fold difference between
the titer for corn avidin versus egg avidin.
Phase I clinical trial
This randomized, double-blind, placebo-controlled Phase I
clinical trial was performed at the McGill University Health
Centre (MUHC) Vaccine Study Center, (Pierrefonds, QC) to
assess the safety and immunogenicity of the plant-produced H5
VLP vaccine (registered at ClinicalTrials.gov: NCT00984945).
The trial was approved by both the Canadian Biologic and
Genetic Therapies Directorate and the Research Ethics Commit-
tee of the MUHC (Final approval, document Dated of September
2
nd 2009.
Subjects
Forty eight healthy adults aged 18–60 years were recruited. The
principal exclusion criteria included significant medical or
neuropsychiatric illness, immunosuppression or immunodeficien-
cy; ongoing febrile illness; history of autoimmune disease; history
of H5N1 vaccination; any vaccination within a 30 day period prior
to enrolment, or planned vaccination between the first vaccination
up to blood sampling at Day 42; use of any investigational or non-
registered product within 90 days prior to study enrolment or
planned use during the study; systemic glucocorticoid therapy;
coagulation disorders or treatment with anticoagulants; history of
allergy to constituents of H5 VLP (H5N1) vaccine or tobacco;
history of severe allergic reactions or anaphylaxis; receipt of a
blood transfusion or immunoglobulins within 90 days of enrol-
ment; pregnancy; lactation; or cancer or treatment for cancer
within 3 years of vaccine administration. Written informed
consent was obtained from all subjects.
Vaccine
H5 VLP vaccine was produced as described above and
formulated with 1% AlhydrogelH prior to vaccination (0.5 mg
aluminium per 0.5 mL dose). Groups of 12 subjects received
vaccines containing 5, 10 or 20 mg of HA (as assessed by SRID
assay). The placebo group received PBS buffer (100 mM
phosphate, 150 mM NaCl, 0.01% Tween 80) + alum (as above).
Procedure
Starting at the lowest dose of H5 vaccine (5 mg/dose), groups of
16 subjects were randomized using block permutation to receive
either active vaccine (n=12) or placebo (n=4) and the study was
completed in 3 waves. At each dose level, safety data for the first 7
days after vaccination was reviewed by an independent panel
before the next group of 12+4 subjects was dosed. The same
staggered approach was used for booster immunizations. All
subjects were immunized by a nurse masked to group assignment.
All immunizations were administered in the deltoid muscle and
subjects were observed for at least 2 hours after each immuniza-
tion for any signs or symptoms of local or systemic reaction. Vital
signs were assessed hourly during this period. Serum was collected
before and 21 days after each immunization and aliquots were
held at 2 to 8uC for biochemistry and haematologic analyses.
Additional aliquots were stored at 220uC until analyzed for
Development of Plant-Made Virus-Like Particle
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period is ongoing.
Safety analysis
A memory aid, rulers and thermometers were given to all
subjects to record adverse events occurring up to Day 21 after each
vaccination. The occurrence of solicited local and systemic
reactions was recorded daily for 7 days following each dose (See
Results section for the list of solicited reactions). Severity was
assessed using a grading scale of 0 to 3 and each reported adverse
event (AE) was reviewed by a masked study investigator (BJW) for
clinical significance and to assign a probability that each AE was
vaccine-related.
Statistical analysis
HI titers in the ferret study were assessed using the Student’s t-
test. For the Phase I clinical trial, demographic data were
compared among treatment group using Fisher’s exact test for
categorical factors and Kruskal-Wallis test for continuous factors.
AEs were coded using the Medical Dictionary for Regulatory
Activities (MedDRAH), version 12.1. The incidence of solicited
signs and symptoms and treatment-emergent AEs were compared
using Fisher’s exact tests (each vaccine dose level versus placebo).
Results were summarized using point estimates and 2-sided 95%
confidence interval (95% CI). For the clinical trial, the principal
HI endpoints were the geometric mean titer (GMT) and geometric
mean increase (GMI); seroconversion was defined as the
proportion of subjects with a fourfold increase in HI titers or a
HI titer $32 when pre-vaccination titer was ,8, seroprotection
was defined as the proportion of subjects with HI titers $40. In
line with European regulatory guidance [10], the principal SRH
endpoints were the geometric mean area (GMA) and the
geometric mean of the increase (GMI); seroconversion was defined
as the proportion of subjects with $50% increase in area post-
vaccination or with GMA $25 mm
2 when pre-vaccination SRH
was negative; seroprotection was defined as the proportion of
subjects with an SRH titer $25 mm
2. For MN titers, as no
protective threshold titer has been defined yet, endpoints were the
geometric mean titer (GMT) and seroconversion was defined as
the proportion of subjects with a fourfold increase in MN titer or a
MN titer $40 when pre-vaccination titer was ,10. For all three
serological assays, the proportion of subjects showing an antibody
response above baseline was reported. Comparisons between HI,
SRH and MN results were performed based on the log10 values of
the titers at Day 42 and by calculating the Spearman correlation
coefficient for selected pairs.
Results
Vaccine production
The H5 VLP vaccine was produced in accordance with Good
Manufacturing Procedures (GMP) for Phase 1 clinical grade
material. The vaccine contained the HA protein of the A/
Indonesia/5/05 H5N1 anchored in plasma membrane from N.
benthamiana cells (Figure 1). Purity assessed by Coomassie-stained
gel was e91% HA. Endotoxin and DNA content were below
typical limits for an injectable biological product of this type.
Vaccine dosages were adjusted based on the Single Radial
ImmunoDiffusion (SRID) assay described above.
The H5 VLP vaccine provides cross-clade protection in
ferrets
The VLP vaccine induced detectable HI titers at all doses tested
(0.7 to 11((g) (Table 1). Twenty-one days after the first dose, 80%
and 87.5% of the ferrets in the 0.7 mg and 1.8 mg groups
respectively and 100% of the animals in the 3.7 and 11.0 mg
groups had developed detectable HI responses against the
homologous strain (A/Indonesia/05/05: clade 1). The highest
HI titer (GMT=40, 95%CI 17–95) after the first dose was
observed in the 11 mg group. Twenty-one days after the second
dose, 100% of ferrets had detectable HI antibodies with GMTs
ranging from 255 (95% CI 94–691) in the 0.7 mg group to 560
(95% CI 234–1324) in the 11 mg group.
The H5 VLP vaccine also induced detectable cross-reactive HI
antibodies in ferrets. Not surprisingly, cross-reactive HI titers were
highest after the second dose (Table 1). The highest GMT was
seen for a clade 2.2 strain (A/turkey/Turkey/1/05) followed by a
clade 2.3 strain (A/Anhui/1/05). All ferrets of the 11 mg group
had detectable HI titers for these two strains but responses were
more variable at lower doses (0.7, 1.8 and 3.7 mg). None of the
placebo-immunized ferrets had detectable HI antibodies for any
strain (data not shown).
HI titers were overall somewhat lower for the clade 1 challenge
strain (A/Vietnam/1203/04) than for clade 2 strains. Twenty-one
days after the second dose, HI titers to A/Vietnam/1203/04 were
detectable in only 75–87.5% of the challenged ferrets (See Table 1).
The highest GMT in challenged groups (GMT=28, 95% CI 11–
71) was seen in the 3.7 mg group.
The challenge with A/Vietnam/1203/04 in the 1.8 and 3.7 mg
and placebo groups revealed complete protection from clinical
illness in the vaccinated animals only. In the first days after
challenge, ferrets in the placebo group had a marked increase in
fever followed by a decrease in body temperature while vaccinated
animals had no important body temperature fluctuations
(Figure 2A). Activity scores in the placebo animals also fell
sharply, starting 3 days after challenge. At day 6, 3 of placebo
recipients were found dead and the other two were euthanized
because they had lost .20% of their body weight. All of the
vaccinated ferrets survived the lethal challenge (Figure 2B and 2C)
and suffered little observable morbidity (Figure 2D). There was no
clear difference in fever, body weight loss or activity scores in the
ferrets vaccinated with either the 1.8 or 3.7 mg dose. Upper
Figure 1. Schematic representation of the structural character-
istics of viral particles and plant-made VLPs. A. Cross-section
showing internal differences. B. Transmission electron microscopy
images of influenza viruses and plant-made VLPs.
doi:10.1371/journal.pone.0015559.g001
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challenge groups 3 days after challenge revealed detectable virus in
the URT all placebo recipients (3/3) but only 1/3 and 2/3 in the
1.8 mg and 3.7 mg groups respectively (Table 2).
Safety and reactogenicity of the H5 VLP vaccine in
humans
The H5 VLP vaccine was well tolerated. Although the sample
size was limited for this first-in-human study, 12 subjects per
treatment group should permit the capture of AEs having 10% or
5% incidences with probabilities of ,72% and ,46% respec-
tively. There were no Serious AEs reported up to Day 42 (21 days
after second dose). The 6-month follow-up period is still ongoing
at time of writing. Pain at injection site, redness and headache
were the most commonly reported local and systemic reactions
(Table 3). Fever .38uC was not reported in any subject. There
were no significant differences in the incidence of either local or
systemic reactions between any vaccine group and the placebo
group except for redness in the 20 mg group after the first dose
only (p=0.04). Local and systemic reactions were mostly mild
(Figure 3) and of short duration. The only reactions reported as
‘severe’ were transient headaches in 1/12 (8.3%) in the 20 mg
group after first dose and in the 10 mg group after the second
dose. However, there was no statistical difference in the over-
all incidence of headache between the vaccine and placebo
recipients.
Immunogenicity of the H5 VLP vaccine in humans
All 48 subjects were included in the safety and immunogenicity
analysis (Figure 4). Within each tested dose group, demographic
characteristics were similar (Table 4). Before vaccination, 1/48
(2.1%), 5/48 (10.4%) and 0/48 (0%) of the subjects had detectable
antibody titers as measured by the HI, SRH and MN assays
respectively (Table 5). After a first dose, the highest GMT and
GMA results were observed in the 20 mg group but differences
with the placebo group were not statistically significant.
HI titers rose to $40 in 16.7, 25 and 50% of the subjects after
the second dose in the 5, 10 and 20 mg groups respectively
(Table 5). No HI antibodies were detected in sera from subjects of
the placebo group. In the vaccinated groups, the GMTs rose
between the first and second doses (p,0.0005) and there was a
clear dose response. After the second dose, HI GMTs were 11.9
(95% CI 5.6–25.5), 18.2 (95% CI, 9.8–33.9) and 29.5 (95% CI,
10.7–80.9) in the 5, 10 and 20 mg groups respectively.
GMI and seroconversion rates were calculated for the 3
serological assays used: HI, MN and SRH. The HI assay provides
an estimate of IgG that can prevent agglutination of erythrocytes
driven by HA of both wild and attenuated viruses. This assay has
limited sensitivity for avian strains [13] but has been used
extensively by regulatory agencies and has established correlates
of protection for seasonal human strains. The MN assays provides
an estimate of antibodies that can prevent infection of cells by live
viruses. This assay is likely a more physiologic measurement of
anti-viral activity than HI, but correlate of protection are not yet
fully understood. The SRH assay measures antibodies that
promote complement-mediated hemolysis induced by influenza
antigen-antibody complexes. Results in this assay are influenced
by both surface glycoproteins (HA and neuraminidase) and
internal viral proteins [13].
Using HI results, the seroconversion rates after the second dose
were 16.7, 25 and 58.3% for the 5, 10 and 20 mg groups
respectively (Table 5). Calculated seroconversion rates were higher
using both the MN (41.7, 50 and 66.7% respectively) and SRH
results (41.7, 50 and 58.3% respectively). Surprisingly, the SRH
assay suggested that 4/12 (25%) of the placebo group had
seroconverted 21 days after the second dose (Table 5). There were
no presumably ‘false’ seroconversions using the other tests (HI and
MN), raising questions about the specificity of SRH assay.
Using HI results, seroprotection rates after the second dose
were 16.7, 25 and 58.3% in the 5, 10 and 20 mgg r o u p s
respectively. Seroprotection rates in these same groups at day 42
were higher by both MN (41.7, 50 and 66.7% respectively) and
SRH (41.7, 41.7 and 75.0% respectively) (Table 5). In terms of
compliance with CHMP guidelines [10], 2 out of three criteria
(seroconversion .40% and GMI.2.5) were met after the second
20 mg dose using HI data, while all three criteria were met using
the SRH data. (seroprotection .70%, seroconversion .40% and
GMI .2.5). The MN assay consistently yielded higher titers than
the HI assay (Tables 5 and 6), supporting the suggestion that the
HI assay is less sensitive than the MN assay for the detection of
anti-H5 antibodies [13,14]. At 21 days after the second dose,
75.0, 75.0 and 91.7% of the subjects in the 20 mg group had
detectable antibody titers as measured by the HI, SRH and MN
assays respectively.
Table 1. Serum HI titers against homologous and heterologous H5N1 strains in ferrets vaccinated with clinical grade material.
Vaccine Dosea Vaccination HI titers
d (95% CI) (number of responders)
Indo/5/05 (clade 2.1) Turkey/Turkey/1/05 (clade 2.2) Anhui/1/05 (clade 2.3) VN/1203/04 (clade 1)
0.7 mg VLP 1
st dose
b 17 (7–45)(4/5) 23 (4–130)(4/5) 5 (3–8)(1/5) ,10(0/5)
2
nd dose
c 255 (94–691)(5/5) 32 (6–178(4/5) 48 (8–307)(4/5) 21 (6–78)(4/5)
1.8 mg VLP 1
st dose
b 23 (16–34)(14/16) 14 (7–29)(9/16) 6 (4–8)(6/16) 5 (5–6)(1/16)
2
nd dose
c 429 (204–902)(8/8) 124 (61–252)(8/8) 74 (26–210)(7/8) 24 (9–67)(6/8)
3.7 mg VLP 1
st dose
b 27 (22–34)(16/16) 31 (19–53)(15/16) 6 (4–8)(6/16) 6 (5–7)(1/16)
2
nd dose
c 382 (236–619)(8/8) 78 (27–229)(7/8) 78 (42–145)(8/8) 28 (11–71)(7/8)
11.0 mg VLP 1
st dose
b 40 (17–95)(5/5) 19 (3–120)(3/5) 5 (3–8)(1/5) ,10 (0/5)
2
nd dose
c 560 (234–1342)(5/5) 106 (53–211)(5/5) 97 (54–173)(5/5) 42 (16–113)(5/5)
aAll vaccines were formulated with Alhydrogel 1% (0.5 mg per dose).
bHI titers measured 21 days after vaccination.
cHI titers measured 14 days after boost vaccination.
dGeometric Mean Titer measured on all animals. HI negative animals were given an arbitrary value of 4 or 5 depending on starting dilution in the HI assay.
doi:10.1371/journal.pone.0015559.t001
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Experiment
Pre-challenge HI GMT
a (fraction of
vaccine responders)
Mean viral load
b (number of positive
animals)
Mean % body
weight change Survival
Indo/5/05 VN/1203/04 URT lungs
After 2
nd dose
1.8 mg VLP 429 (8/8) 24 (6/8) 3.5 (1/3)
c 2.0 (2/3) +2.1 5/5
3.7 mg VLP 382 (8/8) 28 (7/8) 2.5 (2/3)
c ,1.5 (0/3) 20.3 5/5
PBS ,8 (0/8) ,8 (0/8) 3.2 (3/3) 2.25 (1/3) 217.7 0/5
aHI titers measured on sera taken 14 days after last vaccination.
bValues are expressed as log10EID50/ml, mean calculated on positive animals only. Individual values by dose and location: 1.8 mg URT (3.5, , LOD,, LOD) lungs (1.98,
2.0, ,LOD); 3.7 mg URT (2.5, 2.5, , LOD) lung (, LOD, , LOD,, LOD), placebo URT (3.75, 3.33, 2.5) lungs (2.25, 2 x, LOD).
cVirus titration performed on animals sacrificed 3 days post-challenge.
doi:10.1371/journal.pone.0015559.t002
Figure 2. Protection against lethal challenge of control and vaccinated ferrets after challenge with A/Vietnam/1203/04 (H5N1)
virus. Ferrets were immunized twice with the H5 VLP vaccine (A/Indonesia/5/05) or placebo (alum) and were challenged with 10 FLD50 of the A/
Vietnam/1203/04 H5N1 strain 45 days after the booster injection. A. Mean temperature (5 ferrets per group) B. Percent weight loss (at day 6, 3 ferrets
were found dead and the 2 remaining were euthanized due to $20% body weight loss C. Survival D. Activity score.
doi:10.1371/journal.pone.0015559.g002
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measured by the HI and SRH assays (Spearman rs=0.616,
p,0.0001) and between the SRH and MN assays (Spearman
rs=0.602, p,0.0001). The strongest correlation was seen between
the immune response measured by HI and MN assays (Spearman
rs=0.795, p,0.0001).
Cross-reactive antibodies towards H5N1 strains both within
(subclade) and across clades were detected with the HI and MN
assays (Table 6). When measured by HI, cross-reactivity was
highest for the clade 2.3 strain (A/Anhui//1/05) followed by
clade 2.2 strain (A/turkey/Turkey/1/05). It is interesting that HI
antibodies against the clade 1 challenge strain (A/Vietnam/
Figure 3. Rates and severity of local and systemic adverse events (AEs) during the first 7 days after the first and second doses.
Symptoms are graded on the following scale: mild = subject is aware of the AE but it causes no limitation of usual activities, moderate = subject is
aware of the AE and the event causes some limitation of usual activities and severe = AE is of such severity that the subject is unable to carry out
usual activities.
doi:10.1371/journal.pone.0015559.g003
Table 3. Adverse events per group by treatment.
First dose Second dose
Adverse event 5 mg1 0 mg2 0 mg Placebo 5 mg1 0 mg2 0 mg Placebo
Local reaction
Redness 2 (16.7;
0.16–1.00)
4( 3 3 . 3 ;
0.40–1.00)
9 (75.0;
0.66–1.00)
3 (25.0;
0.29–1.00)
8 (66.7;
0.63–1.00)
2 (16.7;
0.16–1.00)
5 (41.7;
0.48–1.00)
5 (41.7;
0.48–1.00)
Swelling 1 (8.3;
0.03–1.00)
0 4 (33.3;
0.40–1.00)
2 (16.7;
0.16–1.00)
2 (16.7;
0.16–1.00)
5 (41.7;
0.48–1.00)
1 (8.3;
0.03–1.00)
3 (25.0;
0.29–1.00)
Pain 11 (91.7;
0.72–1.00)
8( 6 6 . 7 ;
0.63–1.00)
8 (66.7;
0.63–1.00)
7 (58.3;
0.59–1.00)
9 (75.0;
0.66–1.00)
9 (75.0;
0.66–1.00)
8 (66.7;
0.63–1.00)
6 (50.0;
0.54–1.00)
Systemic reactions
F e v e r 00000000
Headache 4 (33.3;
0.40–1.00)
6( 5 0 . 0 ;
0.54–1.00)
2 (16.7;
0.16–1.00)
4 (33.3;
0.40–1.00)
6 (50.0;
0.54–1.00)
5 (41.7;
0.48–1.00)
1 (8.3;
0.03–1.00)
2 (16.7;
0.16–1.00)
Joint aches 0 1 (8.3;
0.03–1.00)
1 (8.3;
0.03–1.00)
0 0 2 (16.7;
0.16–1.00)
0 1 (8.3;
0.03–1.00)
Fatigue 0 4 (33.3;
0.40–1.00)
1 (8.3;
0.03–1.00)
1 (8.3;
0.03–1.00)
4 (33.3;
0.40–1.00)
3 (25.0;
0.29–1.00)
2 (16.7;
0.16–1.00)
2 (16.7;
0.16–1.00)
Muscle aches 2 (16.7;
0.16–1.00)
5( 4 1 . 7 ;
0.48–1.00)
2 (16.7;
0.16–1.00)
3 (25.0;
0.29–1.00)
1 (8.3;
0.03–1.00)
3 (25.0;
0.29–1.00)
00
Feeling of general
discomfort
2 (16.7;
0.16–1.00)
2( 1 6 . 7 ;
0.16–1.00)
0 1 (8.3;
0.03–1.00)
2 (16.7;
0.16–1.00)
2 (16.7;
0.16–1.00)
00
Chills 0 2 (16.7;
0.16–1.00)
0 1 (8.3;
0.03–1.00)
1 (8.3;
0.03–1.00
1 (8.3;
0.03–1.00
00
Data are number(%; 95% CI). Adverse events up to 7 days after vaccination are reported.
doi:10.1371/journal.pone.0015559.t003
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(Table 6).
Immunogenicity of plant-specific glycans in humans
The presence of glycans bearing the plant-specific a-1,3-fucose
and b-1,2-xylose residues and terminal N-acetylglucosamine in the
H5 VLP vaccine was confirmed by Western blot and mass
spectrometry (data not shown). During the Phase I clinical trial, we
sought to determine if IM administration of the vaccine induced
either IgG or IgE responses to these plant-specific glycans.
Although subjects with histories of severe allergies were excluded
from the trial, subjects reporting mild to moderate allergies to
plant derivatives (eg: seasonal allergies, hay fever, allergy to
ragweed, grape or eggplant) were included. Table 7 shows the
number of subjects with allergic histories who were enrolled
(45.8%), including many with histories involving plant derivatives
(39.5%). As shown in Table 8, subjects with allergies to plant
derivatives were found in all groups but the highest incidence was
in the placebo recipients (58.3%). Before vaccination, a total of 7
subjects across all groups had detectable IgG titers to plant
glycans. Among these seven, only two reported mild allergies to
plant derivatives. After two doses of H5 VLP vaccine, only one
subject with a history of allergies (1/12) and four subjects without a
history of allergies (4/24) had small but detectable increases in
serum IgG specific for plant glycans. One non-allergic subject in
the placebo group (1/12) also had an increase in IgG to plant
glycans. No subject in the study, with or without a history of
allergies, had a detectable IgE response to plant glycans either
before or after vaccination. No subject reported allergic symptoms
in the 21 days following each dose.
Discussion
The 2009-10 H1N1 pandemic demonstrated that traditional
egg-based manufacturing technologies are not currently in a
position to provide the volume of vaccines required to respond to a
Figure 4. Subjects disposition. A total of 48 subjects were enrolled in the study and randomized in a 1:1:1:1 ratio to receive two vaccinations of
either 5, 10 or 20 mg of H5 VLP or placebo mixed with Alhydrogel. Vaccinations were administered 21 days apart.
doi:10.1371/journal.pone.0015559.g004
Table 4. Age and sex distribution in different dosing groups
during phase 1 clinical trial.
H5 VLP Vaccine Placebo
5 mg1 0 mg2 0 mg
Age
N 1 21 21 2 1 2
Mean (std. dev.) 45 (8) 42 (11) 33 (13) 40 (12)
(Min.;Max.) (29; 56) (21; 57) (21; 53) (21; 59)
Gender N(%)
Male 5 (41.7%) 3 (25.0%) 7 (58.3%) 6 (50.0%)
Female 7 (58.3%) 9 (75.0%) 5 (41.7%) 6 (50.0%)
doi:10.1371/journal.pone.0015559.t004
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Parameter H5 VLP vaccine Placebo
5 mg HA, n=12 10 mg HA, n=12 20 mg HA, n=12 n=12
Baseline (D0)
HI
GMT 4.0 4.0 4.3 (3.7–5.1) 4.0
Number of subject with positive response (%) 0 0 8.3 (5.5–57.2) 0
Seroprotection (%) 0 0 0 0
SRH
GMA 6.2 (4.4–8.8) 7.8 (5.0–12.1) 7.3 (4.6–11.4) 5.4 (4.4–6.6)
Number of subject with positive response (%) 8.3 (5.5–57.2) 16.7 (2.1–48.4) 16.7 (2.1–48.4) 0
Seroprotection (%) 0 16.7 (2.1–48.4) 16.7 (2.1–48.4) 0
MN
GMT 5.0 5.0 5.0 5.0
Number of subject with positive response (%) 0 0 0 0
3 weeks after first dose (D21)
HI
GMT 4.7 (3.3–6.7) 5.5 (4.0–7.6) 7.5 (4.4–12.9) 4.5 (4.0–10.0)
Number of subject with positive response (%) 8.3 (0.2–38.5) 25 (5.5–57.2) 50 (21.1–78.9) 8.3 (0.2–38.5)
Seroprotection (%) 0 0 8.3 (0.2–38.5) 0
Seroconversion (%) 0 0 8.3 (0.2–38.5) 0
GMI 1.2 (0.8–1.7) 1.4 (1.0–1.9) 1.7 (1.0–3.2) 1.1 (0.9–1.3)
SRH
GMA 9.7 (6.6–14.4) 10.0 (6.3–15.6) 11.2 (6.4–19.7) 6.3 (4.4–8.9)
Number of subject with positive response (%) 41.7 (15.2–72.3) 33.3 (9.9–65.1) 41.7 (15.2–72.3) 16.7 (2.1–48.4)
Seroprotection (%) 8.3 (0.2–38.5) 16.7 (2.1–48.4) 25.0 (5.5–57.2) 0
Seroconversion (%) 16.7 (2.1–48.4) 8.3 (0.2–38.5) 25.0 (5.5–57.2) 16.7 (2.1–48.4)
GMI 1.6 (1.1–2.5) 1.3 (1.1–1.6) 1.5 (0.7–3.5) 1.2 (0.9–1.6)
MN
GMT 6.9 (4.5–10.6) 5.0 7.6 (5.1–11.2) 5.0
Number of subject with positive response (%) 25 (5.5–57.2) 0 33.3 (9.9–65.1) 0
Seroconversion (%) 8.3 (0.2–38.5) 0 16.7 (2.1–48.4) 0
3 weeks after second dose (D42)
HI
GMT 11.9 (5.6–25.5) 18.2 (9.8–33.8) 29.5 (10.7–80.9) 4.0
Number of subject with positive response (%) 66.7 (34.9–90.1) 100 (73.5–100) 75 (42.8–94.5) 0
Seroprotection (%) 16.7 (2.1–48.4) 25.0 (5.5–57.2) 50.0 (21.1–78.9) 0
Seroconversion (%) 16.7 (2.1–48.4) 25.0 (5.5–57.2) 58.3 (27.7–84.8) 0
GMI 3.0 (1.4–6.4) 4.5 (2.4–8.4) 6.8 (2.3–20.3) 1.0
SRH
GMA 15.5 (9.3–26.0) 16.4 (9.4–28.7) 26.2 (13.7–50.1) 7.1 (4.4–11.4)
Number of subject with positive response (%) 50.0 (21.1–78.9) 50.0 (21.1–78.9) 75.0 (42.8–94.5) 25.0 (5.5–57.2)
Seroprotection (%) 41.7 (15.2–72.3) 41.7 (15.2–72.3) 75.0 (42.8–94.5) 8.3 (0.2–38.5)
Seroconversion (%) 41.7 (15.2–72.3) 50.0 (21.1–78.9) 58.3 (27.7–84.8) 25.0 (5.5–57.2)
GMI 2.5 (1.5–5.0) 2.1 (1.4–3.7) 3.6 (2.4–8.7) 1.3 (0.8–2.4)
MN
GMT 16.8 (8.9–31.7) 28.3 (14.9–53.8) 48.1 (20.1–114.9) 5.7 (4.7–7.1)
Number of subject with positive response (%) 83.3 (51.6–97.9) 100 (73.5–100) 91.7 (61.5–99.8) 16.7 (2.1–48.4)
Seroconversion (%) 41.7 (15.2–72.3) 50.0 (21.1–78.9) 66.7 (34.9–90.1) 0
Note: Data in parenthesis are 95% CI. HI denotes Hemagglutination Inhibition assay, SRH Single Radial Hemolysis assay, MN MicroNeutralisation assay, GMT Geometric
Mean Titer. GMI, Geometric Mean of the Increase.
doi:10.1371/journal.pone.0015559.t005
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that egg-based production will ever be able to respond rapidly
enough to influence the first wave of a rapidly spreading pandemic
virus. Our recently described candidate H5 VLP vaccine
produced in plants [5] is a potentially powerful new tool to
address these shortcomings. In our initial report, we demonstrated
that transient expression of the HA protein from H5/Indonesia/
5/05 in N. benthamiania could generate large numbers of H5-
bearing VLPs that were highly immunogenic in mice. Adminis-
tered IM, these H5 VLPs provided excellent protection from
challenge [6]. In a second report, we demonstrated that the first
doses of a plant-made VLP candidate vaccine can be produced
within 3 weeks of the identification of a new pandemic strain [5].
Since no genetic adaptation of the virus is needed and only the HA
sequence from the new strain is required to initiate vaccine
production, this plant-based platform is an interesting alternative
to current technologies to increase global vaccine manufacturing
capacity. In the current work, we present data from in vitro
neutralization studies and in vivo challenge in ferrets that
demonstrate cross-clade protection induced by our candidate
vaccine. We also present safety and early immunogenicity data
from a Phase I, dose-escalation trial in humans. Significantly, this
is the first ever report of administration of a plant-made VLP
vaccine to humans.
Safety is a critical issue for vaccines since public confidence can
make or break immunization programs [15]. There have been no
safety signals in the preclinical studies of our candidate H5 VLP
vaccine (mice, rats, ferrets) and there were no statistical differences
in the incidence or severity of local and systemic reactions between
the vaccine and placebo recipients in the Phase I trial reported
herein. When symptoms occurred, they were typically mild and of
short duration. Since this was a first-in-human study and as the
platform produces glycoproteins with plant-specific N-glycans
particular attention was given to the development of hypersensi-
tivity reactions and to the development of antibodies against plant
glyco-epitopes. i.e. carbohydrate determinants with core b(1,2)-
xylose and a(1,3)- fucose residues. This phase I clinical trial
specifically excluded subjects with background of severe allergic
reactions but allowed subjects with known mild to moderate
allergies to plant derivatives. There were no new hypersensitivity
reactions observed during the trial or convincing evidence of the
induction of antibodies directed against plant N-glycans. Natural-
ly-occurring IgGs to plant-specific carbohydrate determinants
have been reported to occur in 25-50% of healthy human subjects
[16]. This observation is consistent with our finding that 7/48
subjects (14.6%) had detectable IgGs to plant N-glycans before
vaccination. Only 2 of these seven subjects with measurable
antibodies to plant glycans (4.2%) were among the 19 subjects
(39.5%) who declared one or more allergies to plant derivatives.
These data demonstrate that IgGs to plant N-glycans can be found
in subjects who do not suffer from allergies.
None of the two subjects who had both known allergies to plant
derivatives and detectable levels of IgGs to plant-specific N-glycans
before vaccination had increases in this type of IgGs, but one with
known allergies in the VLP group showed an increase, as did 4
other subjects which had no known allergies to plant derivatives.
Thus 13,9% of the VLP subjects showed a detectable increase
while 8,3% of the placebo subjects showed a similar increase, and
this difference has no statistical significance (p=1.0). IgEs to plant-
specific glycans could not be found in any of the 48 subjects. In
light of all these results, it was concluded that in the context of this
study, immunization with the plant-made HA VLPs did not
trigger a response to plant-specific carbohydrate determinants, and
known allergies to plant derivatives and/or presence of detectable
levels of IgGs to plant-specific glycans did not create a
predisposition to an immune response to the N-glycans present
on the HA protein of the VLP vaccine. Although the number of
subjects in this Phase I preclude a definitive conclusion with
Table 6. Cross-reactive antibodies in human subjects at Day 42 for various H5N1 strains.
H5N1 strains
A/Indonesia/5/05 (clade 2.1) A/turkey/Turkey/1/05 (clade 2.2) A/Anhui/1/05 (clade 2.3) A/Vietnam/1203/04 (clade 1)
Outcome 5 mg1 0 mg2 0 mg5 mg1 0 mg2 0 mg5 mg1 0 mg2 0 mg5 mg1 0 mg2 0 mg
HI
Seroconversion (%) 16.7 25.0 58.3 0 8.3 0 8.3 8.3 25.0 0 0 0
$1:40 (%) 16.7 25.0 50.0 0 8.3 0 8.3 0 16.7 0 0 0
GMT 11.9 18.2 29.5 4.9 6.0 7.0 6.0 7.1 8.7 4.3 4.5 4.8
MN
Seroconversion (%) 25.0 25.0 58.3 0 0 8.3
$1:40 (%) 25.0 25.0 58.3 0 0 8.3
GMT 14.2 28.3 48.7 6.55 6.74 12.1
doi:10.1371/journal.pone.0015559.t006
Table 7. Allergies reported by subjects.
Group
At screening, number of subjects reporting
ongoing allergy (number;%)
Any known
allergy
Allergy to any plant
derivative
(1)
5 mg H5 VLP 5 (41.7%) 5 (41.7%)
10 mg H5 VLP 5 (41.7%) 3 (25.0%)
20 mg H5 VLP 4 (33.3%) 4 (33.3%)
Placebo 8 (66.6%) 7 (58.3%)
Total in vaccine groups 14 (38.8%) 12 (33.3%)
Total in all groups 22 (45.8%) 19 (39.5%)
(1)as expressed by seasonal allergies, hay fever, allergy to ragweed or allergy to
grapes or eggplant.
doi:10.1371/journal.pone.0015559.t007
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are reassuring for the continued development of these vaccines.
The lack of both allergic reactions and increases in IgE following
vaccination may be explained by the fact that the H5 glycans
present in this VLP vaccine bear terminal N-acetylglucosamine
(GlcNAc). which could conceivably have shielded the more
proximal b(1,2)- xylose and a(1,3)-linked fucose residues, thereby
preventing the cross-linking of IgEs and degranulation of mast cells
and basophils as reported by Altmann [17].
Prior to the Phase I trial, ferret studies of the H5 VLP vaccine
demonstrated the induction of good levels of neutralizing
antibodies both within- and across clades as well as complete
protection from cross-clade lethal challenge. It is interesting that
both clinical and virologic data in the ferret study revealed
excellent protection from the A/Vietnam challenge despite
relatively low HI antibody titres (Table 1). This observation
confirms that we do not yet fully understand the correlates of
protection for influenza virus infection [18]. Although preliminary
data suggest that the plant-made H5 VLPs have powerful effects
on the human innate immune system (data not shown), it is not yet
known if this vaccine stimulates only antibody production or both
humoral and cellular arms of the immune system in either ferrets
or in humans. Studies of both innate and adaptive cell-mediated
responses induced by the H5 VLP vaccine are currently
underway, as suggested in the CHMP guideline for licensing of
pandemic vaccines [10].
As a secondary outcome, the Phase I trial provided a ‘first look’
at the immunogenicity of the H5 VLP vaccine at doses of 5, 10
and 20 mg adjuvanted with alum. Our decision to use an alum-
adjuvanted formulation in the Phase I study was based, in part, on
lower antibody responses in ferrets exposed to the candidate VLP
vaccine without alum (data not shown). Furthermore, several
human trials of egg-based split and whole inactivated virion H5N1
vaccines had suggested modest benefits of aluminium adjuvants
[11,19,20,21,22]. It is noteworthy that our candidate H5 VLP
vaccine induced potent antibody responses in mice in the absence
of alum [6]. Future studies in ferrets as well as our planned Phase
II studies in humans will include groups without alum.
Immunogenicity criteria for licensing candidate influenza
vaccines vary slightly between jurisdictions but are largely based
on serologic responses measured by two assays, Hemagglutination
Inhibition (HI) and Single Radial Hemolysis (SRH). Although the
HI assay has long been the standard serologic test for influenza, it
may be less sensitive for avian strains such as H5N1 [13,14]. The
SRH assay is more sensitive for H5N1 strains [23,24] but may also
detect antibodies to internal proteins and therefore overestimate
the humoral response to surface glycoproteins [13]. Because of the
inherent limitations of these assays, vaccine developers increas-
ingly rely on the MN as a more functional measure of
immunogenicity [24,25]. Finally, most of the reagents available
for all of these assays have been developed and standardized for
vaccines produced in eggs and may, as a result, be biased to
recognize antibodies against antigens from influenza viruses grown
in eggs. In light of these limitations and uncertainties, we used all
three serological assays to evaluate the humoral response induced
by the plant-made H5 VLP vaccine in humans. Although
premature in some respects, it may be useful to discuss these data
in the context of the current CHMP criteria for licensure of
pandemic vaccines [10]
Using this approach, the 12 subjects in the 20 mg group met 2/3
of the CHMP criteria based on HI testing (seroconversion .40%,
GMI .2.5) and 3/3 based on the SRH assay (seroprotection
.70%, seroconversion .40%, GMI .2.5). As noted above
however, the SRH assay also detected higher rates of apparent
seroconversion and seroprotection in the placebo group than the
HI test (Table 5). Overall, the results of the three assays were
highly correlated although HI results were always lower than those
obtained with MN or SRH. The known lack of sensitivity of the
HI test for anti-H5 antibodies [23,24] is the most likely
explanation for these differences. It is harder to explain the
observations that 2/12 of the subjects in the 20 mg group had
seroprotective SRH titers before vaccination and 2/12 subjects in
the placebo group had a 150% increase in SRH area during the
42 days study period (Table 5). Given that the SRH assay will also
detect antibodies directed against non-HA antigens (eg: NA and
internal proteins) it is possible that these paradoxical SRH results
were the result of exposure to circulating H1N1 influenza viruses
with high homology for the neuraminidase protein (or other
internal proteins). This hypothesis is supported to some extent by
the observation that the placebo group also experienced small
increases in apparent antibody titers using the MN assay, which
can also detect antibodies to a broader range of targets than just
HA. Irrespective of the CHMP criteria, it is interesting that 87.5%
of the subjects who received two doses of either the 10 or 20 mg
Table 8. Antibodies to plant-specific sugar moieties.
Group Before immunisation (D0) After two immunisations (D42)
Number of subjects with detectable
IgGs to plant-specific sugar moieties
Number of subject with an increase in
IgGs to plant-specific sugar moieties
Number of subject with an increase in
IgEs to plant-specific sugar moieties
Total
subjects
In subjects who
reported known
allergy to plant
component
Total
subjects
In subjects who
reported known
allergy to plant
component
Total
subjects
In subjects who
reported known
allergy to plant
component
5 mg H5 VLP 1/12 1/5 2/12 1/5
a 0/12 0/5
10 mgH 5
VLP
3/12 1/3 1/12 0/3 0/12 0/3
20 mgH 5
VLP
2/12 0/4 2/12 0/4 0/12 0/4
Placebo 1/12 0/7 1/12 0/7 0/12 0/7
Total 7/48 (14,6%) 2/19 (10,5%) 6/48 (12,5%) 1/19 (5,2%) 0/48 (0%) 0/19 (0%)
aNot the same subject who had detectable Abs to plant-specific sugar moieties before immunisation.
doi:10.1371/journal.pone.0015559.t008
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mounted detectable MN responses. These data are particularly
encouraging in light of the fact that traditional, egg-based split
H5N1 vaccines showed only modest immunogenicity in humans at
doses as high as 45 mg with or without alum as an adjuvant
[11,20]. Furthermore, a recent meta analysis examining the
relationship between HI titer and clinical protection against
influenza including data from 5899 adult subjects and 1304
influenza cases suggested that the 50% protection threshold
traditionally associated with HI titers of 1/40 [25] might be better
set at 1/20 [26]. Such a shift in the protective threshold would also
suggest that the 50% protection threshold was achieved by the
20 mg dose group in our Phase I.
Overall, these results are reassuring for the continued clinical
development of this candidate H5 VLP vaccine. Although
evidence is accumulating that newer adjuvants can significantly
boost H5N1 responses when combined with split-virus antigens
[27–28], experience with the pH1N1 pandemic revealed serious
limitations for egg-based antigen production in terms of both
speed and volume. Our plant-produced H5 VLP vaccine has the
potential to respond to both of these deficiencies. Even at the
current estimate of 20 mg per dose, the surge capacity, speed of
response and simplicity of the plant-based technology, combined
with the good safety profile shown in this Phase I study suggest that
plant-made VLP vaccines should be further evaluated for use in
pre-pandemic and pandemic situations.
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